Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03031340
Other study ID # 11-01-004
Secondary ID
Status Terminated
Phase Phase 3
First received
Last updated
Start date May 2012
Est. completion date September 2012

Study information

Verified date August 2019
Source Montefiore Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To see if the administration of 3 dosses of pregabalin (1 dose preoperative, 2 doses postoperative) will reduce the postoperative opiate requirements of patients undergoing spinal fusion surgeries of two or more vertebrae.


Description:

Introduction

Postoperative pain is often thought to be inadequately treated in half of all surgical procedures . Postoperative pain management in patients undergoing spine surgery is often difficult and challenging. The challenges of opioid tolerance and paucity of efficient opioid sparing agents makes pain management even more complex. Preoperative strategies that can minimize postoperative pain include proper surgical technique, which would avoid or lessen nerve injury, and the use of preemptive analgesia. Studies have shown that the intensity of acute postoperative pain correlates with the risk of developing persistent pain. Post operative pain results from the direct activation of nociceptors, inflammation, and in some cases direct nerve injury to the nerves.

The data on preemptive analgesia are inconclusive . The concept, however, has sparked interest in mechanism-based analgesia and highlighted the process of central sensitization as a target for analgesic intervention .

The use of opioids is limited by their side effect profile and by the poor response of certain types of pain . The multiplicity of mechanisms involved in pain suggests that combination of opioid and non-opioid analgesic drugs will enhance analgesia. The concomitant reduction in opioid requirements, anticipated with the use of multimodal therapy, can also be expected to reduce side effects.

Pregabalin is a lipophilic gamma-amino-butyric acid (GABA) analog with anticonvulsant, anxiolytic and sleep-modulating properties. The effectiveness of pregabalin has been demonstrated in several pain models including neuropathic pain , , incisional injury and inflammation . Several previous studies conducted found that the use of gabapentin, the predecessor of pregabalin, reduced post operative pain and opioid requirements and decreased the number of opioid related adverse events , . Pregabalin is the pharmacologically active S enantiomer of 3-aminomethyl-5-methyl hexanoic acid; it has a similar pharmacological profile to gabapentin . Like gabapentin, pregabalin also binds to the α-2-δ subunit of voltage gated calcium channels, reducing the release of excitatory neurotransmitters: glutamate, norepinephrine, serotonin, dopamine and substance-P. It blocks the development of hyperalgesia and inhibits central sensitization , . Pregabalin has greater absorption, bioavailability, anticonvulsant, anti-hyperalgesic and anxiolytic properties than gabapentin , .

Rationale for selecting spine surgeries. Low back pain is a major medical problem and a significant source of disability for people under 45 years of age . Spine surgeries are considered to be among the most complex, and long-lasting. The postoperative period is particularly challenging for efficient pain management. Postoperative pain may be due to nociceptive pain as well as hyperalgesia secondary to surgical trauma. Central sensitization is a key mechanism in the development and maintenance of chronic pain, particularly for neuropathic pain and pain after spine surgery .

Rationale for using pregabalin

Animal studies in surgical pain models and clinical studies of inflammatory pain in volunteers demonstrated that both of these interventions can cause allodynia and hyperalgesia- these are both susceptible to pregabalin and its analogues , .

The sensitization of dorsal horn neurons has been demonstrated in acute pain models and may be responsible for the development of chronic pain after surgery , , . The ability of pregabalin to reduce the hyperexcitability of dorsal neurons induced by tissue damage confirms its role in preemptive analgesia . Its anxiolytic effect and ability to prevent opioid tolerance could also be beneficial . Alternately, antihyperalgesia drugs like pregabalin may block pathological pain, while leaving the physiological pain (with its protective function) intact. This class of agents function through opiate independent pathways and do not affect gut motility .

Pharmacodynamics and Pharmacokinetics:

Pregabalin is an FDA-approved drug available in 50-300 mg/day (the FDA-recommended maximum is 300mg/day). It is rapidly absorbed following oral administration with peak plasma concentration occurring between 0.7-1.3hrs. The mean oral bioavailability is 90% after 1-300mg of single oral dose. The elimination half-life is 5.5-6.5 hrs independent of dose and repeated administration. Plasma clearance is essentially equivalent to renal clearance. The elimination rate is nearly proportional to creatinine clearance and dose reduction is recommended in patients with low creatinine clearance. Ninety percent of the dose is excreted in the urine .

Adverse events of pregabalin Pregabalin is generally well tolerated and associated with mild to moderate adverse events which are dose dependent. The most frequently reported (22-29%) are dizziness and somnolence. Other less common adverse events reported are dry mouth, peripheral edema, blurred vision and inability to concentrate .

Hypothesis:

Our hypothesis is that pre-operative administration of pregabalin can reduce the central neural sensitization, efficiently reverse inflammatory hyperalgesia and can cause opioid sparing effect. These actions of pregabalin will reduce the amount of opioids need by the patient intraoperatively and in the immediate postoperative period. The reduction of opioids will lessen opioid related adverse events and will augment the perioperative satisfaction level.


Recruitment information / eligibility

Status Terminated
Enrollment 3
Est. completion date September 2012
Est. primary completion date September 2012
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age : > 18 years old

- Fusion of > two vertebrae

- Capacity to provide consent

- ASA I-IV

- Ability to swallow capsules

Exclusion Criteria:

- Plan of care includes intubated ICU admission post-op

- Allergy to gabapentin or pregabalin

- Two week prior use of pregabalin

- Significant renal dysfunction (creatinine level >2)

- Severe cardiovascular disease

- History of frequent headaches or dizziness

- Significant hepatic dysfunction (LFT's > 4 times the normal ranges)

- Active usage of alcohol or illicit substances three days prior to surgery

- History of seizure disorders

- Taking medication for anxiety, antiseizure, and psychiatric diagnoses

- Re-operation patients

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Pregabalin
On the day of the surgery, 1hour + 15 minutes before the surgery starts, the subject will receive either 300mg of pregabalin or a similarly packaged placebo. On post operative day one, 150 mg of pregabalin or placebo will be given in two doses 12hrs apart.
Other:
placebo
placebo

Locations

Country Name City State
United States Montefiore Medical Center Bronx New York

Sponsors (1)

Lead Sponsor Collaborator
Montefiore Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Postoperative Opioid Requirement The primary objective of this study is to evaluate the role of three doses of pregabalin on intra and postoperative (48hrs) opioid requirements in patients undergoing fusion of two or more vertebrae. 48 hours
Secondary Pain Using the Visual Analog Scale (VAS) Pain Score evaluate pain using the visual analog scale (VAS) pain score at two hrs post-op, the morning following surgery 24 hours and 48 hours post-op 2 hours, 24 hours, 48 hours
Secondary Incidence of 48 Hours Post Operative Nausea and Vomiting Find the incidence of 48 hours post operative nausea and vomiting in the target population 48 hours
Secondary Post Operative Cognitive Function 48 hours post operative headache, dizziness, sedation and blurred vision 48 hours
Secondary Pre-operative Anxiety Measure the level of pre-operative anxiety using the visual analog scale (VAS) 24 hours prior to surgery
Secondary Anesthesia Satisfaction To measure the level of overall anesthesia satisfaction among the two groups at discharge. 24 hours post surgery
See also
  Status Clinical Trial Phase
Completed NCT04037059 - Impact of Body Habitus (Arm Span and Abdominal Girth) on Activities of Daily Living (ADL)
Recruiting NCT03883022 - Vancomycin Powder Combined With Autogenous Bone Graft as a Prevention for Post-operative Infection for Spine Surgery N/A
Not yet recruiting NCT06003010 - Yoga for Adolescent Idiopathic Scoliosis (AIS) Patients N/A
Completed NCT01136590 - Multicenter, Randomized Placebo-controlled Clinical Trial to Evaluate the Effect of Perioperative Use of Tranexamic Acid on Transfusion Requirements and Surgical Bleeding in Major Spine Surgery Phase 4
Completed NCT01235650 - Prevalence of Inadvertent Hyperventilation During Intraoperative Anesthetic Care N/A
Completed NCT03459404 - Sufentanil NanoTab PCA System/15 mcg for Acute Post-Operative Pain in Vertebral Surgery: A Preliminary Investigation
Recruiting NCT05010148 - A Clinical Trial of Intravenous Lidocaine After Spinal Surgery to Prevent Delirium and Reduce Pain Phase 3
Recruiting NCT04605120 - Allogeinic Bone Paste N/A
Completed NCT03826329 - Risk Factors of Second Surgery for Adjacent Segment Disease Following Anterior Cervical Discectomy and Fusion
Recruiting NCT04601363 - Personalized Spine Study Group (PSSG) Registry
Recruiting NCT05323448 - Efficacy of ARISTA-AH for Restoring Hemostasis Following Posterior Long-segment Spinal Fusion. N/A
Completed NCT00994656 - Is Pleth Variability Index (PVI) a Surrogate for Pulse Pressure Variations (PPV) in Pediatric Spine Fusion (SF) Surgery? N/A
Completed NCT00152152 - Use of Radiostereometric Analysis Beads (RSA) to Measure Motion in the Spine, Following Lumbar Spinal Surgery N/A
Terminated NCT03425799 - Efficacy and Safety of Tranexamic Acid in Spinal Fusion Surgery Phase 3
Not yet recruiting NCT06368245 - Durability of Suppl. Rod Constructs-SuppleMentAry Rod Technique for Long-segment Posterior Instrumented Spinal Fusions
Withdrawn NCT03908203 - Minimally Invasive Surgery Techniques for One-level Degenerative Lumbar Deformities Correction N/A
Terminated NCT03378973 - The Effects of Dexmedetomidine Dose on Motor Evoked Potentials Phase 4
Completed NCT05936047 - Bone Marrow Clot for Posterior Lumbar Fusion N/A
Not yet recruiting NCT03692845 - Minimally Invasive Versus Open Transforaminal Lumbar Interbody Fusion N/A
Completed NCT00152165 - Use of Radiostereometric Analysis (RSA) Following Spinal Fusion Versus the DYNESYS Stabilization System N/A